ERBB2 and breast carcinoma: Studies have shown that it is even possible to revert tamoxifen resistance in specific breast cancer cells through the use of NFkB inhibitors,30 and to observe a direct correlation between NFkB activity and HER-2/neu expression, thereby suggesting a possible role for COX activity in tumor progression.26